HU0104674A3 - Cancer treatment composition containing natural plant essential oils - Google Patents

Cancer treatment composition containing natural plant essential oils

Info

Publication number
HU0104674A3
HU0104674A3 HU0104674A HU0104674A HU0104674A3 HU 0104674 A3 HU0104674 A3 HU 0104674A3 HU 0104674 A HU0104674 A HU 0104674A HU 0104674 A HU0104674 A HU 0104674A HU 0104674 A3 HU0104674 A3 HU 0104674A3
Authority
HU
Hungary
Prior art keywords
essential oils
plant essential
treatment composition
cancer treatment
natural plant
Prior art date
Application number
HU0104674A
Other languages
Hungarian (hu)
Other versions
HU0104674A2 (en
Original Assignee
Ecosmart Technologies Inc Fran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11127198P priority Critical
Application filed by Ecosmart Technologies Inc Fran filed Critical Ecosmart Technologies Inc Fran
Publication of HU0104674A2 publication Critical patent/HU0104674A2/en
Publication of HU0104674A3 publication Critical patent/HU0104674A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/898Orchidaceae (Orchid family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Pharmaceutical compositions containing plant essential oils, natural or synthetic, or mixtures or derivatives thereof, for the prevention and treatment of soft tissue cancer in mammals.
HU0104674A 1998-12-07 1999-12-07 Cancer treatment composition containing natural plant essential oils HU0104674A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11127198P true 1998-12-07 1998-12-07

Publications (2)

Publication Number Publication Date
HU0104674A2 HU0104674A2 (en) 2002-06-29
HU0104674A3 true HU0104674A3 (en) 2003-01-28

Family

ID=22337523

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104674A HU0104674A3 (en) 1998-12-07 1999-12-07 Cancer treatment composition containing natural plant essential oils

Country Status (24)

Country Link
US (8) US20030017215A1 (en)
EP (3) EP1137427A1 (en)
JP (3) JP2002531511A (en)
KR (1) KR20010080692A (en)
CN (1) CN100448454C (en)
AR (3) AR020021A1 (en)
AT (1) AT307601T (en)
AU (3) AU1841900A (en)
BR (1) BR9916879A (en)
CA (3) CA2353476A1 (en)
CZ (1) CZ20011979A3 (en)
DE (1) DE69928000T2 (en)
ES (1) ES2247858T3 (en)
HU (1) HU0104674A3 (en)
ID (1) ID29393A (en)
IL (1) IL143488D0 (en)
MX (3) MXPA01005598A (en)
NO (1) NO20012774L (en)
NZ (1) NZ527850A (en)
PL (1) PL349028A1 (en)
RU (1) RU2252772C2 (en)
TR (1) TR200101481T2 (en)
WO (3) WO2000033858A1 (en)
ZA (1) ZA200104611B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9916879A (en) * 1998-12-07 2001-11-06 Ecosmart Technologies Inc Composition and method for treating cancer using natural vegetable essential oils
DE10113513A1 (en) * 2001-03-20 2002-10-02 Medinnova Ges Med Innovationen Drug combination of kinase inhibitor and neurotropic factor, useful for treating and/or preventing nerve and/or glial cell damage, e.g. associated with neurodegenerative diseases
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
NZ538637A (en) * 2002-08-12 2008-01-31 Lonza Ag Antimicrobial compositions
CA2407755A1 (en) * 2002-10-11 2004-04-11 The Hospital For Sick Children Inhibition of vegf secretion
DE10259619A1 (en) * 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Use of a TRPM8 activating substance for tumor treatment
MD2231C2 (en) * 2003-03-05 2004-02-29 Ион КАЛМЫК Composition for treatment of oncologic pathologies
JP2007502860A (en) 2003-04-24 2007-02-15 ヴァンダービルト ユニバースィティ Compositions and methods for controlling insects
US20060263403A1 (en) * 2003-04-24 2006-11-23 Essam Enan Compositions and methods for controlling insects involving the tyramine receptor
US7622269B2 (en) * 2004-03-19 2009-11-24 Tyratech, Inc. Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
WO2005002582A2 (en) * 2003-07-02 2005-01-13 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
DE10341933A1 (en) * 2003-09-11 2005-04-14 Lts Lohmann Therapie-Systeme Ag Medicated skin patches containing essential oils for the treatment of colds and methods of making the same
SE0401302D0 (en) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Inhibition of recognized phosphorylation
WO2006120495A1 (en) * 2005-05-13 2006-11-16 Advanced Scientific Developements Pharmaceutical composition comprising an antiviral agent, an antitumour agent or an antiparasitic agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
CN100553628C (en) 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 The application of 2-bromo-isovanillin in the anticancer and/or radiation of preparation, chemotherapy sensitizing medicine
ES2627033T3 (en) 2006-06-27 2017-07-26 Tyratech, Inc. Compositions for use in the treatment of a parasitic infection in a mammalian subject
US8685471B2 (en) * 2006-07-17 2014-04-01 Tyratech, Inc. Compositions and methods for controlling insects
US20090099135A1 (en) * 2007-01-16 2009-04-16 Tyratech, Inc. Pest control compositions and methods
JP2011021013A (en) * 2009-06-19 2011-02-03 Ube Industries Ltd Method for producing aromatic methyl alcohol compound having oxyl group
EP2480090B1 (en) 2009-09-24 2013-11-06 Unilever NV Disinfecting agent comprising eugenol, terpineol and thymol
US8003393B1 (en) * 2010-02-09 2011-08-23 Panasonic Corporation Method for determining whether or not a mammal is affected with a lung cancer
US8962679B2 (en) * 2010-07-08 2015-02-24 The Administrators Of The Tulane Educational Fund Daidzein analogs as treatment for cancer
FR2967055B1 (en) * 2010-11-08 2012-12-21 Biochimie Appliquee Solabia COSMETIC COMPOSITIONS BASED ON PIPERONYL ESTERS AND THEIR USE IN SOSMETICS AS ANTI-AGING SKIN AND DEPIGMENTING AGENT
US9408870B2 (en) 2010-12-07 2016-08-09 Conopco, Inc. Oral care composition
WO2012104568A1 (en) * 2011-02-02 2012-08-09 GILHOLM, Stephen Philip Compositions of monoterpenoids for stimulating the immune system
WO2012177799A1 (en) * 2011-06-20 2012-12-27 Atheronova Operations, Inc. Subcutaneous fat reduction
BR112014009479B8 (en) 2011-11-03 2019-01-29 Unilever Nv personal cleaning liquid composition and external surface disinfection method
KR101357395B1 (en) 2012-08-06 2014-02-05 영남대학교 산학협력단 Novel tetrazolohydrazone derivative and parmaceutical composition for preventing or treating cancer containing thereof
WO2015102448A1 (en) * 2014-01-03 2015-07-09 전북대학교 산학협력단 Hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide and method for preparing same
US9950071B2 (en) * 2014-01-03 2018-04-24 Industrial Cooperation Foundation Chonbuk National University Hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide and method for preparing same
JP6669665B2 (en) * 2014-03-20 2020-03-18 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Methods and compositions for using cinnamaldehyde and zinc for weight management
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
DE102015119552A1 (en) * 2015-10-23 2017-04-27 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpenhaltige composition for the treatment of cancer and / or cancer
CN105294465A (en) * 2015-12-08 2016-02-03 天津医科大学 Chiral ionone alkaloid derivative with breast cancer metastasis prevention function and medical application of chiral ionone alkaloid derivative
CN105559074B (en) * 2016-02-03 2019-02-12 华南农业大学 A kind of tealeaves volatile essential oil is preparing the application in cancer-preventing health product or anticancer drug
KR101798203B1 (en) * 2016-09-23 2017-11-15 전북대학교 산학협력단 Hybrid anticancer prodrug for creating cinnam aldehyde with quinone metide by acidic pH and esterase, and method for preparing the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS57106697A (en) * 1980-12-22 1982-07-02 Kyowa Hakko Kogyo Co Ltd Easily absorbable map composition and preparation containing the same
FR2557452B1 (en) * 1983-12-28 1986-08-14 Roussel Uclaf NOVEL COMPOSITIONS FOR SKIN CARE CONTAINING PRIMER OIL AND RATE TISSUE TRAITS
DE3515253C1 (en) * 1985-04-27 1986-06-19 Werner Walter Use of isopropanolic solutions of diphenyl as topical pharmaceutical
DE3634697A1 (en) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets DENTAL MATERIAL TO CONTROL CARIES AND PERIODONTOSE
DE3826846A1 (en) * 1988-08-06 1990-02-08 Goedecke Ag ALKOXY-4 (1H) -PYRIDONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DRUGS
DE3829200A1 (en) * 1988-08-29 1990-03-01 Kaempgen Dieter Dr Phil Active compounds against the immunodeficiency disease AIDS
JP2746453B2 (en) * 1990-03-13 1998-05-06 鐘紡株式会社 Active oxygen scavenger
EP0448029B1 (en) 1990-03-23 1995-12-20 Nippon Kayaku Kabushiki Kaisha Novel pharmaceutical uses of forskolin derivatives
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
FR2683454B1 (en) 1991-11-13 1995-06-09 Pf Medicament Bactericidal pharmaceutical composition.
DK0663831T3 (en) * 1991-12-13 1995-07-26 Searle & Co transdermal azidothymidine
EP0567948B1 (en) * 1992-04-29 1996-09-11 NORDICA S.p.A Braking device on a roller skate
JPH07506822A (en) * 1992-05-19 1995-07-27
FR2697133B1 (en) * 1992-10-28 1995-01-13 Transbiotech Biocidal and / or biostatic composition and its applications.
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
FR2706771B1 (en) * 1993-06-21 1995-12-01 Pelletier Jacques
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5626854A (en) 1994-03-17 1997-05-06 Kao Corporation Bath composition
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
IL131628D0 (en) * 1997-03-04 2001-01-28 Wisconsin Alumni Res Found Method of suppressing tumor growth with combinations of isoprenoids and statins
AU7165798A (en) 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
DE69841434D1 (en) * 1997-07-18 2010-02-25 Novo Nordisk Healthcare Ag USE OF FVIIa OR FVIIAi FOR THE TREATMENT OF ENDOTHELIAL MALFUNCTION OR INHIBITION OF THE ANGIOGENESIS
WO1999048469A1 (en) * 1998-03-20 1999-09-30 The Procter & Gamble Company Composition for aroma delivery
AT407821B (en) * 1998-03-24 2001-06-25 Franz Dr Stueckler Medium based on natural substances
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1123106B1 (en) * 1998-10-23 2003-07-23 Dieter Ebert Composition containing eugenol and polyphenols and use of such a composition for wound healing
KR100312622B1 (en) * 1998-11-03 2002-02-28 김송배 Stabilized anticancer composition mainly composed of herbal medicine and its manufacturing method
BR9916879A (en) * 1998-12-07 2001-11-06 Ecosmart Technologies Inc Composition and method for treating cancer using natural vegetable essential oils
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Also Published As

Publication number Publication date
BR9916879A (en) 2001-11-06
NO20012774D0 (en) 2001-06-06
AU2167100A (en) 2000-06-26
JP2002531512A (en) 2002-09-24
DE69928000D1 (en) 2005-12-01
US20030017215A1 (en) 2003-01-23
HU0104674A2 (en) 2002-06-29
EP1137425A1 (en) 2001-10-04
US20030108622A1 (en) 2003-06-12
AR020019A1 (en) 2002-03-27
CN1329498A (en) 2002-01-02
CA2353516A1 (en) 2000-06-15
DE69928000T2 (en) 2006-06-08
NO20012774L (en) 2001-06-06
KR20010080692A (en) 2001-08-22
NZ527850A (en) 2004-07-30
AR020020A1 (en) 2002-03-27
WO2000033858A1 (en) 2000-06-15
US20020182268A1 (en) 2002-12-05
CN100448454C (en) 2009-01-07
CA2353476A1 (en) 2000-06-15
US6812258B2 (en) 2004-11-02
PL349028A1 (en) 2002-07-01
AT307601T (en) 2005-11-15
IL143488D0 (en) 2002-04-21
EP1137426B1 (en) 2005-10-26
US20030108623A1 (en) 2003-06-12
MXPA01005598A (en) 2003-07-14
US20080015249A1 (en) 2008-01-17
WO2000033857A9 (en) 2001-12-13
JP2002531511A (en) 2002-09-24
CA2353475A1 (en) 2000-06-15
ID29393A (en) 2001-08-30
AU2167000A (en) 2000-06-26
WO2000033856A1 (en) 2000-06-15
US7291650B2 (en) 2007-11-06
US7008649B2 (en) 2006-03-07
TR200101481T2 (en) 2001-09-21
US20040156922A1 (en) 2004-08-12
ES2247858T3 (en) 2006-03-01
RU2252772C2 (en) 2005-05-27
ZA200104611B (en) 2001-12-13
US20030017218A1 (en) 2003-01-23
WO2000033857A1 (en) 2000-06-15
JP2002531513A (en) 2002-09-24
MXPA01005545A (en) 2003-07-14
EP1137427A1 (en) 2001-10-04
AU1841900A (en) 2000-06-26
CZ20011979A3 (en) 2001-10-17
MXPA01005641A (en) 2003-07-14
AR020021A1 (en) 2002-03-27
EP1137426A1 (en) 2001-10-04
US20040146595A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
HU0104674A3 (en) Cancer treatment composition containing natural plant essential oils
MX9702415A (en) Antineoplastic cocoa extracts, methods for making, using.
ES2120274T3 (en) Use of an extract of a non photosynthetic filament bacteria and composition.
MX9709941A (en) New pharmaceutical composition with anaesthetic effect.
MX9700223A (en) Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
SA1603B1 (en) Celecoxib compounds
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
MX9709684A (en) Use of vitamin d4 derivatives for treating skin disorders.
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
BR9608488A (en) Use of vitamin d4 derivatives in the treatment of cancer
YU13301A (en) Muscarinic agonists and antagonists
ZA200103565B (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer.
UA61968C2 (en) Pharmaceutical compositions containing vitamin d and calcium, their manufacture and therapeutic use
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
SE9802937D0 (sv) Novel compounds
PL179608B1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
BG105275A (en) Tan-1057 derivatives
NO983177L (en) Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
MX9704034A (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof.
NZ326345A (en) Composition containing diosgenin
ES2175661T3 (en) Derivatives of isoflavona, procedures for the preparation of the same and pharmaceutical compositions containing them.
HU0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
UA31995A (en) Composition for prevention and treatment of hypogalactia
UA15363A (en) Composition for treating open wounds
UA72462C2 (en) Compounds with properties of releasing the growth hormone and a pharmaceutical composition based thereon